X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in adult patients with a history of atherosclerotic cardiovascular disease.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 09, 2024
Details:
NewAmsterdam TA-8995 (obicetrapib), CETP inhibitor, in combination with Ezetimibe. It is being evaluated in Phase III clinical trial studies with patients for the treatment of Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2024
Details:
The net proceeds will be used for the development of TA-8995 (obicetrapib). It is a selective cholesteryl ester transfer protein inhibitor that potently decreases (LDL-C) as well as increases (HDL-C), which is used for the treatment of atherosclerotic Cardiovascular disease.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $173.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 13, 2024
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor. It is currently being investigated in patients with early Alzheimer’s disease and at least one copy of the apolipoprotein E4 mutation.
Lead Product(s): Obicetrapib
Therapeutic Area: Neurology Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 21, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 05, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, oral, low-dose CETP inhibitor that NewAmsterdam is developing to potentially overcome the limitations of current LDL-lowering treatments.
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 24, 2023
Details:
TA-8995 (obicetrapib) is a next-generation, non statin, oral once-daily, low-dose CETP inhibitor having the potential for lowering LDL-C, if approved. It is currently being investigated in combination with ezetimibe as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
Proceeds from this transaction will be used for three ongoing phase 3 trials, BROADWAY, BROOKLYN and PREVAIL, evaluating the effect of TA-8995 (obicetrapib) in patients with atherosclerotic cardiovascular disease and heterozygous familial hypercholesterolemia.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: $235.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement November 23, 2022
Details:
Obicetrapib (TA-8995) is an oral, low-dose and once-daily CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 05, 2022
Details:
Emerging data reinforce combination lipid-lowering therapy as first-line strategy for very high-risk patients, supporting the development of TA-8995 (obicetrapib) as adjunct to high-intensity statins.
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Lifesciences Acquisition Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 29, 2022
Details:
Treatment with TA-8995 (obicetrapib) in patients on high-intensity statin therapy was observed to have statistically significant impact on LDL-C, as well as significant impacts on ApoB, non-HDL-C, HDL-C and Lp(a), additional key measures of cardiovascular disease risk.
Lead Product(s): Obicetrapib,Atorvastatin
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 11, 2022
Details:
BROOKLYN evaluates TA-8995 (obicetrapib) as an adjunct to diet and maximally tolerated lipid lowering therapy in patients requiring additional lowering of low-density lipoprotein cholesterol (LDL-C).
Lead Product(s): Obicetrapib
Therapeutic Area: Genetic Disease Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2022
Details:
NewAmsterdam is investigating TA-8995 (obicetrapib), a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Lifesciences Acquisition Corporation
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger July 25, 2022
Details:
NewAmsterdam is investigating TA-8995 (obicetrapib), a next-generation oral, low-dose and once-daily CETP inhibitor, as the preferred LDL-C-lowering therapy for high-risk cardiovascular disease (“CVD”) patients.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Frazier Healthcare Partners
Deal Size: $235.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 25, 2022
Details:
Under the collaboration agreement, NewAmsterdam will retain all rights to commercialize obicetrapib in cardiovascular diseases, if approved, in the rest of the world, as well as rights to develop certain forms of TA-8995 for other diseases such as Alzheimer's disease.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Menarini
Deal Size: $1,061.5 million Upfront Cash: $121.0 million
Deal Type: Licensing Agreement June 28, 2022
Details:
TA-8995 (Obicetrapib) is a next-generation oral, low-dose and once-daily CETP inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 06, 2022
Details:
TA-8995 (obicetrapib) is next-generation CETP inhibitor, initially in development for patients at high risk for cardiovascular disease as an adjunct to maximally tolerated statin therapy, both as a monotherapy and in a fixed-dose combination with ezetimibe.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 19, 2022
Details:
ROSE2 study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, in combination with ezetimibe, a cholesterol absorption inhibitor, in patients who are currently receiving high-intensity statin therapy.
Lead Product(s): Obicetrapib,Ezetimibe
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 05, 2022
Details:
PREVAIL evaluates whether obicetrapib, a novel cholesteryl ester transfer protein inhibitor, lowers the risk of adverse cardiovascular outcomes in individuals with ASCVD, who are not adequately controlled despite maximally tolerated lipid-modifying therapies.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 01, 2022
Details:
TA-8995 (obicetrapib) is a selective cholesteryl ester transfer protein inhibitor in development for lowering low-density lipoprotein cholesterol (LDL-c) and preventing major adverse cardiovascular events.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2022
Details:
Phase 3 BROADWAY trial primary objective is to evaluate the effect of TA-8995 (obicetrapib), on LDL-c levels at day 84. Study evaluates obicetrapib, a novel cholesteryl ester transfer protein inhibitor, as an adjunct to diet and maximally tolerated lipid-lowering therapy.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2022
Details:
Results of ROSE study demonstrated that patients on statin therapy who received 5mg of obicetrapib saw a reduction in LDL-c of 42% and patients who were part of the 10mg cohort experienced 51% reduction v/s baseline, while the placebo experienced 7% reduction v/s baseline.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2021
Details:
ROSE was designed as a placebo-controlled, double-blind, randomized, Phase 2 dose-finding study to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to high-intensity statin therapy.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 28, 2021
Details:
Funding will support initiation and finalization of Phase 3 development of obicetrapib, a potent ApoB and LDL-c lowering small molecule drug, intended for patients not well-controlled on statins.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: TA-8995
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Morningside Ventures
Deal Size: $196.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing January 14, 2021
Details:
NewAmsterdam Pharma is currently working with the U.S. Food and Drug Administration (FDA) on a comprehensive Phase 3 clinical development program, including a cardiovascular outcome trial (CVOT) for obicetrapib.
Lead Product(s): Obicetrapib
Therapeutic Area: Cardiology/Vascular Diseases Product Name: AMG 899
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: NewAmsterdam Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition August 25, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
